Jade Biosciences announces preclinical data on potentially best-in-class Jade301 antibody for dermatomyositis at EADV 2026
JBIO•Jade Biosciences said Jade301 showed high-affinity, selective IFN-β binding, greater potency than dazukibart and an approximately 25-day half-life in primates; a Phase 1 trial is set to begin in Q4 2026, with interim data expected in H2 2027.
1. Jade301 preclinical findings
Jade Biosciences announced preclinical data for Jade301, a half-life-extended anti-IFN-β monoclonal antibody in development for dermatomyositis. The company said the antibody showed predictable muscle distribution and was well tolerated at all subcutaneous doses in non-human primates.
2. Clinical trial timeline
Jade Biosciences said a Phase 1 trial is expected to begin in Q4 2026, with interim data expected in H2 2027.
